# A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial.

*biotech · news · 2026-05-20 · Fox News*

## Key points

- The TroFuse-005 trial is the first global Phase 3 to show survival improvement over chemo for endometrial cancer.
- Sacituzumab tirumotecan is the first antibody-drug conjugate to achieve such results in this setting.
- The trial included 776 advanced endometrial cancer patients whose disease progressed after both platinum chemo and immunotherapy.
- Merck has not yet disclosed detailed statistics on survival benefit and response rates for sacituzumab tirumotecan.

**Companies:** Merck
**Countries:** United States, Italy

[Read the full story on Fox News](https://www.foxnews.com/health/new-drug-approach-offers-hope-patients-recurrent-aggressive-cancers)

---

Canonical: https://newsio.io/n/bf2253a1-a008-4be3-abf3-9d5f8b9b1b54/a-new-treatment-for-endometrial-cancer-demonstrated-strong-potential-in-a-phase
Summarized by Newsio from Fox News. https://newsio.io/how-it-works